alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Journals › JAMA Neurology

Research published in JAMA Neurology

Every study in the alzhub library that its record lists as published in JAMA Neurology, summarised in plain English and scored out of 100.

These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news.

How the records spell this journal (2 spellings)

The 20 highest-scoring

  1. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology JAMA Neurology · 2024-03-01 · · Peer-reviewed

    A commercially available plasma p-tau217 immunoassay accurately identified biological Alzheimer's disease, comparable to cerebrospinal fluid biomarkers, with reproducible cut-offs across cohorts. Using a three-range reference reduced confirmatory testing by about 80%, which could make diagnosis less invasive and more accessible.

  2. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials JAMA Neurology · 2025-05-01 · · Peer-reviewed

    This analysis of donanemab trials found that amyloid-related imaging abnormalities (ARIA) are an adverse event associated with donanemab treatment that requires safety monitoring. Several baseline factors were linked to higher or lower risk of ARIA-E.

  3. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease JAMA neurology · 2022-01-01 · · Peer-reviewed

    This report describes amyloid-related imaging abnormalities in two phase 3 studies of aducanumab in people with early Alzheimer disease. The provided text does not include information on whether aducanumab affected cognitive or functional outcomes.

  4. Research Criteria for the Behavioral Variant of Alzheimer Disease: A Systematic Review and Meta-analysis JAMA neurology · 2022-01-01 · · Peer-reviewed
  5. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry JAMA Neurology · 2023-12-01 · · Peer-reviewed

    In 68,756 East Asian, Hispanic, Black and White individuals, links between APOE genotype and Alzheimer disease differed by ancestry: the ε2 genotypes (ε2/ε2, ε2/ε3) showed no association with AD in East Asian people (OR 0.97), and Hispanic people showed weaker APOE associations that overall ancestry could not explain. A previously reported higher risk for women with the ε3/ε4 genotype was seen again in White individuals, but at ages 60 to 70 (OR 1.48), and also in a combined analysis of Black and Hispanic individuals (OR 1.72). These are statistical associations; they do not give anyone a personal risk figure and do not point to a treatment.

  6. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial JAMA neurology · 2022-12-01 · · Peer-reviewed

    In this exploratory secondary analysis of the TRAILBLAZER-ALZ randomized trial, which randomized 272 people with early symptomatic Alzheimer disease, blood levels of pTau217 and glial fibrillary acidic protein were significantly lower with donanemab than with placebo "as early as 12 weeks after the start of treatment", and those changes were correlated with the percent change in amyloid. Blood amyloid-β 42/40 and neurofilament light chain showed "no significant differences" between arms at the end of treatment. This record reports blood-marker changes only: it does not say whether memory or daily function changed, and it is not evidence that the treatment cures or prevents Alzheimer's disease.

  7. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials JAMA neurology · 2022-11-01 · · Peer-reviewed

    These two phase 3 trials of crenezumab in early Alzheimer's disease reported no new safety signals, with amyloid-related imaging abnormalities with edema being rare, mild, and transient. The provided text does not report efficacy results.

  8. Association of Hearing Aids and Cochlear Implants With Cognitive Decline and Dementia: A Systematic Review and Meta-analysis JAMA Neurology · 2023-02-01 · · Peer-reviewed

    This meta-analysis of 31 studies with 137,484 participants found that hearing aid and cochlear implant use was associated with a 19% decrease in hazards of long-term cognitive decline and a 3% improvement in short-term cognitive test scores. It suggests hearing restoration may help reduce cognitive decline, but it does not show a treatment or cure for dementia.

  9. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers JAMA neurology · 2023-04-01 · · Peer-reviewed

    This study followed people from two research cohorts, BioFINDER-1 and WRAP, who had amyloid in the brain but were described as cognitively unimpaired: 171 people in the main analyses. It asked whether blood markers predict later memory and thinking decline at this "preclinical" stage. The authors conclude that the blood test plasma P-tau217 "may be used as a complement to CSF or PET" when choosing participants for trials of new disease-modifying treatments. That is a finding about trial recruitment, not about a treatment, and our record does not include the figures showing how well the test predicted decline.

  10. Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial JAMA neurology · 2020-02-01 · · Peer-reviewed

    This trial tested whether minocycline could slow cognitive and functional decline in people with mild Alzheimer disease over 24 months. The available text does not report the main results, so no conclusion about its effect can be drawn from this summary.

  11. Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis JAMA neurology · 2019-01-01 · · Peer-reviewed

    This 2019 systematic review and meta-analysis pooled 94 prospective cohort studies to ask whether four MRI signs of "covert" vascular brain injury (white matter hyperintensities, covert brain infarcts, microbleeds and perivascular spaces) predict later stroke, dementia or death. The one result kept in alzhub's copy is that extensive white matter hyperintensity burden went with a higher rate of stroke (hazard ratio 2.45; 95% CI 1.93–3.12), and the authors conclude the markers "have major clinical significance". The studies were observational and no treatment was tested, so it does not show that preventing these scan changes prevents stroke or dementia.

  12. Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US JAMA neurology · 2022-06-01 · · Peer-reviewed

    This analysis estimates that about 1 in 3 Alzheimer disease and related dementia cases in the US are associated with 8 modifiable risk factors, most prominently midlife obesity, physical inactivity, and low educational attainment. It reports that these associated risk factors differ by sex and race and ethnicity, but it does not show that changing them prevents dementia.

  13. Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial JAMA neurology · 2018-04-01 · · Peer-reviewed

    In this subgroup analysis of 1109 participants, the effect of a multidomain lifestyle intervention on cognition did not differ significantly between APOE ε4 carriers and noncarriers. The authors say whether benefits are more pronounced in carriers should be further investigated.

  14. Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis JAMA neurology · 2021-01-01 · · Peer-reviewed

    African American people are about twice as likely as their non-Hispanic White neighbours to develop Alzheimer's, so this study looked for genetic risk signals in 2,784 African American people with Alzheimer's and 5,222 without it. It found one genome-wide significant region near the IGF1R gene and 6 weaker "suggestive" regions. Of 25 risk regions known from non-Hispanic White studies, only 7 (APOE, ABCA7, TREM2, BIN1, CD2AP, FERMT2 and WWOX) were implicated in this group. These are statistical associations, not proven causes, and the study tested no treatment or prevention.

  15. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials JAMA neurology · 2020-02-01 · · Peer-reviewed

    These trials were designed to assess whether lanabecestat slows progression of early and mild Alzheimer's disease compared with placebo. The provided text does not report the efficacy results.

  16. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial JAMA neurology · 2022-08-01 · · Peer-reviewed

    In this phase 2 trial, semorinemab did not show a difference from placebo on the primary outcome measure of clinical dementia rating. Similar increases on the Clinical Dementia Rating-Sum of Boxes score were seen in the placebo and semorinemab groups.

  17. Deferiprone in Alzheimer Disease: A Randomized Clinical Trial JAMA neurology · 2025-01-01 · · Peer-reviewed

    In this trial of 81 participants with Alzheimer disease, deferiprone accelerated cognitive decline on the primary outcome compared with placebo, driven by worsening performance on executive function tests, even though it decreased iron in the hippocampus. Hippocampal volume loss was not affected, and exploratory analysis found increased volume loss in some other brain regions with deferiprone.

  18. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies JAMA Neurology · 2024-01-01 · · Peer-reviewed

    Plasma p-tau217 was most strongly associated with amyloid positivity and performed best among the biomarkers tested, with high sensitivity and specificity, and results were validated in an independent cohort. This suggests plasma p-tau217 could help select patients with Alzheimer's disease for antiamyloid immunotherapies.

  19. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study JAMA neurology · 2019-08-01 · · Peer-reviewed

    Over about 7 years in 60 older adults (median age 73) at the preclinical stage of Alzheimer's, an earlier rise in amyloid on brain scans was associated with later changes in tau, and tau changes were associated with declining thinking scores. A statistical model linked starting amyloid to cognition 7 years later through these successive changes, a pattern consistent with amyloid coming first, then tau, then decline, though it shows association, not cause. The authors say this supports repeated tau-PET to track progression and repeated amyloid-PET to spot the earliest changes; no treatment was tested.

  20. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging JAMA neurology · 2021-08-01 · · Peer-reviewed

    In 1,431 people from 8 cohorts in South Korea, Sweden and the US, ranging from cognitively unimpaired to Alzheimer dementia, baseline tau PET predicted change in MMSE scores over about 2 years more strongly than MRI cortical thickness or amyloid PET (R² 0.35 vs 0.24 vs 0.17 across all participants). The authors call tau PET "a promising tool for predicting cognitive change" that "may support the prognostic process" in early-stage Alzheimer's. This record does not include the results for each stage separately or for the replication cohort, and the study did not test any treatment.

See all 325 studies, with filters →

Newest additions

All 325, newest first →

By review status

Other journals

The library by subject →